Effects of plasmalogens on systemic lipopolysaccharide-induced glial activation and β-amyloid accumulation in adult mice

Annals of the New York Academy of Sciences

Volumn 1262, Issue 1, 2012, Pages 85-92

  Katafuchi, Toshihiko ^a   Ifuku, Masataka ^a   Mawatari, Shiro ^b   Noda, Mami ^c   Miake, Kiyotaka ^d   Sugiyama, Masaaki ^d   Fujino, Takehiko ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b Institute of Rheological Function of Food   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d Marudai Food Co Ltd   (Japan)

Author keywords

Alzheimer's disease; Microglia; Neuroinflammation; Phospholipids

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-16]; CORN OIL; LIPOPOLYSACCHARIDE; PLASMALOGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DRUG EFFECT; HIPPOCAMPUS; MALE; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN;

MUS; ZEA MAYS;

EID: 84864132951     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06641.x     Document Type: Article

References (52)

1. Boehm, G.W. et al. 2005. Effects of intraperitoneal lipopolysaccharide on Morris maze performance in year-old and 2-month-old female C57BL/6J mice. Behav. Brain Res. 159: 145-151.
2. Lee, J.W., et al. 2008. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of β-amyloid generation. J. Neuroinflammation 5: 37.
3. O'mara, S.M., K.N. Shaw & S. Commins. 2001. Lipopolysaccharide causes deficits in spatial learning in the watermaze but not in BDNF expression in the rat dentate gyrus. Behav. Brain Res. 124: 47-54.
4. Blasko, I., et al. 2001. Ibuprofen decreases cytokine-induced amyloid β production in neuronal cells. Neurobiol. Dis. 8: 1094-1101.
5. Sastre, M., et al. 2003. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-γ agonists modulate immunostimulated processing of amyloid precursor protein through regulation of β-secretase. J. Neurosci. 23: 9796-9804.
6. Yan, Q., et al. 2003. Anti-inflammatory drug therapy alters β-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 23: 7504-7509.
7. Farooqui, A.A. & L.A. Horrocks. 2001. Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia. Neuroscientist 7: 232-245.
8. Farooqui, A.A. & L.A. Horrocks. 2001. Plasmalogens, phospholipase A2, and docosahexaenoic acid turnover in brain tissue. J. Mol. Neurosci. 16: 263-272; discussion 279-284.
9. Farooqui, A.A. 2010. Studies on plasmalogen-selective phospholipase A2 in brain. Mol. Neurobiol. 41: 267-273.
10. Khaselev, N. & R.C. Murphy. 1999. Susceptibility of plasmenyl glycerophosphoethanolamine lipids containing arachidonate to oxidative degradation. Free Radic. Biol. Med. 26: 275-284.
11. Engelmann, B. 2004. Plasmalogens: targets for oxidants and major lipophilic antioxidants. Biochem. Soc. Trans. 32: 147-150.
12. Maeba, R. & N. Ueta. 2003. Ethanolamine plasmalogen and cholesterol reduce the total membrane oxidizability measured by the oxygen uptake method. Biochem. Biophys. Res. Commun. 302: 265-270.
13. Yavin, E. & S. Gatt. 1972. Oxygen-dependent cleavage of the vinyl -ether linkage of plasmalogens: 2. Identification of the low-molecular-weight active component and the reaction mechanism. Eur. J. Biochem. 25: 437-446.
14. Ginsberg, L., et al. 1995. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. Brain Res. 698: 223-226.
15. Guan, Z., et al. 1999. Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J. Neuropathol. Exp. Neurol. 58: 740-747.
16. Han, X., D.M. Holtzman & D.W. McKeel, Jr. 2001. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J. Neurochem. 77: 1168-1180.
17. Ginsberg, L., J.H. Xuereb & N.L. Gershfeld. 1998. Membrane instability, plasmalogen content, and Alzheimer's disease. J. Neurochem. 70: 2533-2538.
18. Goodenowe, D.B., et al. 2007. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. J. Lipid Res. 48: 2485-2498.
19. Wood, P.L., et al. 2010. Circulating plasmalogen levels and Alzheimer disease assessment scale-cognitive scores in Alzheimer patients. J. Psychiat. Neurosci. 35: 59-62.
20. Mawatari, S., et al. 2009. Simultaneous preparation of purified plasmalogens and sphingomyelin in human erythrocytes with phospholipase A1 from Aspergillus orizae. Biosci. Biotechnol. Biochem. 73: 2621-2625.
21. Mawatari, S., Y. Okuma & T. Fujino. 2007. Separation of intact plasmalogens and all other phospholipids by a single run of high-performance liquid chromatography. Anal. Biochem. 370: 54-59.
22. Folch, J., M. Lees & G.H. Sloane Stanley. 1957. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226: 497-509.
23. Querfurth, H.W. & F.M. LaFerla. 2010. Alzheimer's disease. N. Engl. J. Med. 362: 329-344.
24. Blasko, I., et al. 1999. TNFα plus IFNγ induce the production of Alzheimer β-amyloid peptides and decrease the secretion of APPs. FASEB J. 13: 63-68.
25. Reiss, D., K. Beyer & B. Engelmann. 1997. Delayed oxidative degradation of polyunsaturated diacyl phospholipids in the presence of plasmalogen phospholipids in vitro. Biochem. J. 323(Pt 3): 807-814.
26. Zoeller, R.A., et al. 2002. Increasing plasmalogen levels protects human endothelial cells during hypoxia. Am. J. Physiol. Heart Circ. Physiol. 283: H671-H679.
27. Urano, S., et al. 1997. Oxidative injury of synapse and alteration of antioxidative defense systems in rats, and its prevention by vitamin E. Eur. J Biochem./FEBS 245: 64-70.
28. Lohner, K., et al. 1991. Stabilization of non-bilayer structures by the etherlipid ethanolamine plasmalogen. Biochim. Biophys. Acta 1061: 132-140.
29. Breckenridge, W.C., et al. 1973. Adult rat brain synaptic vesicles. II. Lipid composition. Biochim. Biophys. Acta 320: 681-686.
30. Cordy, J.M., et al. 2003. Exclusively targeting β-secretase to lipid rafts by GPI-anchor addition up-regulates β-site processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. U.S.A. 100: 11735-11740.
31. Riddell, D.R., et al. 2001. Compartmentalization of β-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. Curr. Biol. 11: 1288-1293.
32. Butterfield, D.A. & C.M. Lauderback. 2002. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 32: 1050-1060.
33. Christen, Y. 2000. Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr. 71: 621S-629S.
34. Grimm, M.O.W., et al. 2011. Plasmalogen synthesis is regulated via alkyl-dihydroxyacetonephosphate-synthase by amyloid precursor protein processing and is affected in Alzheimer's disease. J. Neurochem. 116: 916-925.
35. Cimini, A., et al. 2003. TNFα downregulates PPARδ expression in oligodendrocyte progenitor cells: implications for demyelinating diseases. Glia 41: 3-14.
36. Üllen, A., et al. 2010. Mouse brain plasmalogens are targets for hypochlorous acid-mediated modification in vitro and in vivo. Free Rad. Biol. Med. 49: 1655-1665.
37. Latorre, E., et al. 2003. Signaling events mediating activation of brain ethanolamine plasmalogen hydrolysis by ceramide. Eur. J. Biochem. 270: 36-46.
38. Munn, N.J., et al. 2003. Deficiency in ethanolamine plasmalogen leads to altered cholesterol transport. J. Lipid Res. 44: 182-192.
39. Frears, E.R., et al. 1999. The role of cholesterol in the biosynthesis of β-amyloid. Neuroreport 10: 1699-1705.
40. Puglielli, L., R.E. Tanzi & D.M. Kovacs. 2003. Alzheimer's disease: the cholesterol connection. Nat. Neurosci. 6: 345-351.
41. Simons, M., et al. 1998. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. U.S.A. 95: 6460-6464.
42. Kojro, E., et al. 2001. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc. Natl. Acad. Sci. U.S.A. 98: 5815-5820.
43. Chauhan, N.B. 2003. Membrane dynamics, cholesterol homeostasis, and Alzheimer's disease. J. Lipid. Res. 44: 2019-2029.
44. Farooqui, A.A., L.A. Horrocks & T. Farooqui. 2007. Modulation of inflammation in brain: a matter of fat. J. Neurochem. 101: 577-599.
45. Calon, F., et al. 2004. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43: 633-645.
46. Palacios-Pelaez, R., W.J. Lukiw & N.G. Bazan. 2010. Omega-3 essential fatty acids modulate initiation and progression of neurodegenerative disease. Mol. Neurobiol. 41: 367-374.
47. Schmitz, G. & J. Ecker. 2008. The opposing effects of n-3 and n-6 fatty acids. Prog. Lipid Res. 47: 147-155.
48. Grimm, M.O.W., et al. 2011. Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms. J. Biol. Chem. 286: 14028-14039.
49. Walsh, D.M. & D.J. Selkoe. 2004. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44: 181-193.
50. Oksman, M., et al. 2006. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on β-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol. Dis. 23: 563-572.
51. Scott, B.L. & N.G. Bazan. 1989. Membrane docosahexaenoate is supplied to the developing brain and retina by the liver. Proc. Natl. Acad. Sci. U.S.A. 86: 2903-2907.
52. Bernoud, N., et al. 1999. Preferential transfer of 2-docosahexaenoyl-1-lysophosphatidylcholine through an in vitro blood-brain barrier over unesterified docosahexaenoic acid. J. Neurochem. 72: 338-345.